Profusa, Inc. (PFSA)
Nasdaq: PFSA · Surgical & Medical Instruments & Apparatus · New York, NY · filing with the SEC since 2021
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Report filed | Apr 15, 2026 | Mar 31, 2025 | Feb 26, 2024 | Mar 6, 2023 | Mar 18, 2022 |
| Revenue | · | 100,000 | · | · | · |
| For lenders | |||||
| Interest and dividend income | · | · | · | 8,937,503 | · |
| Interest and investment income | · | 425,416 | 2,248,538 | 2,579,268 | · |
| Research and development | 2,804,000 | 1,608,000 | · | · | · |
| General and administrative | 24,902,000 | 2,992,000 | · | · | · |
| Total operating expenses | 27,706,000 | 4,600,000 | · | · | · |
| Total costs and expenses | · | 1,351,038 | 1,508,683 | 1,270,554 | · |
| Operating income | -27,706,000 | -4,500,000r | -1,508,683 | -1,270,554 | · |
| Interest expense | 2,521,000 | 4,424,000 | · | · | · |
| Other income (expense), net | 16,000 | 5,000 | · | · | · |
| Total non-operating income (expense) | -8,117,000 | -4,730,000r | 3,127,383 | 8,937,503 | · |
| Income before income taxes | · | -8,631,106 | 1,618,700 | 7,666,949 | · |
| Income tax expense | · | 80,513 | 456,790 | 499,211 | · |
| Net income | -35,823,000 | -9,230,000r | 1,161,910 | 7,167,738 | · |
| Earnings per share, basic | -107.01 | -357.14r | 0.12 | 0.30 | · |
| Earnings per share, diluted | -107.01 | -357.14r | 0.12 | 0.30 | · |
| Weighted average shares, basic | 334,762 | 25,844r | 5,193,750 | 5,193,750 | · |
| Weighted average shares, diluted | 334,762 | 25,844r | 5,193,750 | 5,193,750 | · |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenuesInterest and dividend income what its loans and securities earned
us-gaap:InterestIncomeOperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesTotal costs and expenses every operating cost, the cost of revenue included
us-gaap:OperatingCostsAndExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding